{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000071","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.200480+00:00","generated_at":"2026-05-21T23:48:14.459623+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Editas Q1 net loss $76.1M ($0.92/share); cash $221M runway into Q2 2027","bullets":["Net loss $76.1M ($0.92 per share) vs $62.0M loss in Q1 2024; revenue $4.7M (up from $1.1M).","R&D expenses fell to $26.6M from $48.8M; restructuring charges $40.9M from reni-cel discontinuation.","Cash, equivalents, and marketable securities $221.0M; expected to fund operations into Q2 2027.","Amy Parison appointed CFO; previously SVP Finance and Corporate Controller at Editas since 2022.","Federal Circuit vacated PTAB decision on CRISPR/Cas9 patents; remanded for further review."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000071","json":"https://secwatch.observer/filing/0001650664-25-000071.json","markdown":"https://secwatch.observer/filing/0001650664-25-000071.md","text":"https://secwatch.observer/filing/0001650664-25-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/0001650664-25-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000071/edit-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:48:14.459623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}